PaxMedica IncNASDAQ PXMD Stock Report

PaxMedica, Inc. is an early clinical stage biopharmaceutical company. The company is headquartered in Tarrytown, New York and currently employs 2 full-time employees. The company went IPO on 2022-08-19. The firm is focused on developing on the development of anti-purinergic drug therapies (APT) for the treatment of disorders with intractable neurologic symptoms, ranging from neurodevelopmental disorders, including autism spectrum disorder (ASD), to Myalgic Encephalomyelitis/Chronic Fatigue Syndrome (ME/CFS). Its product candidates include PAX-101 and PAX-102. Its lead program, PAX-101, is an intravenous formulation of suramin, in the treatment of ASD and the advancement of the clinical understanding of using that agent against other disorders, such as ME/CFS and Long COVID-19 Syndrome (LCS). The company is also focused on developing PAX-101 for the treatment of East African Human-African Trypanosomiasis (HAT), which is caused by the parasite Trypanosome brucei rhodesiense. The company is also focused on developing PAX-102, which is an intranasal formulation of suramin for neurologic indications.